[Pharmacotherapy of obesity].
Long-term success in obesity therapy is difficult to obtain, therefore drug therapy appears to be helpful. Until today, end-point studies for obesity drugs beyond the improvement of individual surrogate parameters are still missing. For all available drugs, medical treatment can be recommended only for a limited period of time due to the data of the studies and under consideration of side effects. Although a weight reduction leads to an improvement of cardiovascular risk factors and hence a reduction of cardiovascular morbidity and mortality should be expected, no study could prove it so far. Despite the positive influence on individual surrogate parameters, the use of the present available therapies appears underwhelming. In this overview the approved substances and perspectives of new therapeutic concepts are represented.
Rotthoff
Thomas
T
Klinik for Endokrinologie, Diabetologie und Rheumatologie, Universitätsklinikum Düsseldorf. rotthoff@med.uni-duesseldorf.de
Scherbaum
Werner A
WA
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy / Q000628:therapy*; D000077403:Orlistat; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D000077285:Rimonabant; D000077236:Topiramate
D019440:Anti-Obesity Agents; D000927:Anticonvulsants; D003503:Cyclobutanes; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D000077236:Topiramate; D005632:Fructose; D000077403:Orlistat; D000077285:Rimonabant; C058254:sibutramine